FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2784286543> ?p ?o ?g. }

• W2784286543 abstract "AIM AND OBJECTIVE: To formulate and evaluate Prednisolone retention enema as dispersible tablet withvehicle.Prednisolone is a type of medicine called corticosteroid. It decreases immunesystem’s response in various diseases to reduce symptoms such as pain, swelling and allergictype reactions. Prednisolone is 4 times more potent than hydrocortisone, also more selectiveglucocorticoid. It reduces inflammation by stopping cells from releasing chemicals thatnormally help to produce immune and allergic responses47-49.Riboflavin is an integral component of two enzymes FAD (flavin adeninedinucleotide) and FMN (flavin mononucleotide). FAD and FMN are involved in the activityof electron transport chain, an essential component of energy metabolism. Prednisolonedecreases the inflammation by inhibiting the migration of polymorphonuclear leukocytes andreversal of increased capillary permeability. It suppresses the immune system by reducing theactivity and protection of the lymphocytes and eosinopril. Riboflavin helps in this place toincrease the energy metabolism in lymphocytes and eosinopril50.The objectives of this study are followingTo formulate dispersible tablet and vehicle as enema formulation.To select excipients and find any incompatibility between the drug and excipients.To formulate Prednisolone dispersible tablet and vehicle.To perform the precompression and tablets evaluation parameters.To select the best formulation of dispersible tablet.To prepare rectal suspension using best formulation of dispersible tablet.To perform in-vitro drug release study for rectal suspension.To conduct Microbiology studies for the rectal suspension.To perform stability studies for the selected formulation of dispersible tablet.Formulation of vehicle solution for suspending Prednisolone dispersible tabletFormulation of rectal suspension using selected formulation of dispersible tablet.Evaluation of rectal suspensionAppearance, Colour, pH, Viscosity, In-vitro drug release study, Microbiological evaluation. Accelerated stability studies.SUMMARY: This work demonstrate that the formulation and evaluation of Prednisolone retentionenema as the dispersible tablet with vehicle for the effective treatment of UC. It was carriedout by performing the preformulation studies, formulation of Prednisolone dispersible tablet,formulation of vehicle, evaluation parameters, microbiology studies, in-vitro release studiesand stability studies.For pure Prednisolone, preformulation studies such as angle of repose, bulk density,tapped density, compressibility index, Hausner’s ratio, moisture content and particlesize analysis were performed. The preformulation results revealed that thePrednisolone having poor flow properties, so it may requires glidants. The moisturecontent showed within 1% and the particle size was found to be fine powder.Drug – excipients incompatibility study was performed by physical observation. Thatthere were no physical changes between drug and excipients. Thus it was concludedthat the excipients selected for the formulation were compatible with Prednisolone.Prednisolone dispersible tablets were formulated by direct compression method, wetgranulation method and slugging method using crospovidone as superdisintegrant.The formulated powder/granule blend was evaluated for precompression parameterslike angle of repose, bulk density, tapped density, Hausner’s ratio, compressibilityindex and moisture content. The results obtained indicate that F6 formulationformulated by slugging method has good flow property. The moisture content waswithin 1%.The formulated tablets were evaluated for hardness, thickness, weight variation,friability, disintegration time, wetting time, water absorption ratio, in-vitro dispersiontime, uniformity of dispersion and drug content. All these parameters were found tobe within the limits for F6 formulation. IR spectroscopic analysis was carried out to determine the compatibility of drug andexcipients. The IR spectrum showed that the drug was compatible with excipients,which was used in the F6 formulation.From the data’s obtained from precompression parameters and tablet evaluation F6formulation was selected for further studies.The rectal suspension was prepared by using F6 formulation.pH and viscosity of the rectal suspension were carried out and the pH was found to be6.2 and the viscosity was found to be 55.9 cps.In-vitro drug release of Prednisolone from F6 formulation in rectal suspension was99.07 ± 0.02 % at 60 minutes.The microbiology studies for the rectal suspension with F6 formulation were carriedout to determine the presence/absence of microorganisms in the formulation. Theresults showed that there was absence of microorganisms in F6 formulation in rectalsuspension. So the formulation was microbiologically stable.The accelerated stability studies were performed for F6 formulation at three differenttemperatures such as 40 ± 20 C, 280 ± 20 C and 450 ± 20 C for a period of three months.In this storage condition for the three months period, there were no changes in all thetablets physical parameters.The accelerated stability studies of F6 formulation in rectal suspension (in vitro drugrelease) was also performed by stored in three different storage conditions for theperiod of three months. The results showed that there were no changes in percentagedrug release.CONCLUSION: Formulation and evaluation of Prednisolone retention enema as dispersible tablet withvehicle for the effective treatment of UC was successfully carried out.Preformulation studies of powder/granules, formulation of Prednisolone dispersibletablets, formulation of vehicle, tablets evaluation parameters, in-vitro release study,microbiological evaluation and accelerated stability studies (three different temperatures)were performed. From all the above observations it was concluded that the formulation F6 byslugging method was better one compared to the other formulations.Thus it can be concluded that the Prednisolone retention enema as dispersible tabletwith vehicle possesses promising future delivery of rectal formulation of drugs in suspensionform for the effective treatment of UC." @default.
• W2784286543 created "2018-01-26" @default.
• W2784286543 creator A5045811414 @default.
• W2784286543 date "2017-10-01" @default.
• W2784286543 modified "2023-09-27" @default.
• W2784286543 title "Formulation and Evaluation of Prednisolone Retention Enema as Dispersible Tablet with Vehicle" @default.
• W2784286543 hasPublicationYear "2017" @default.
• W2784286543 type Work @default.
• W2784286543 sameAs 2784286543 @default.
• W2784286543 citedByCount "0" @default.
• W2784286543 crossrefType "dissertation" @default.
• W2784286543 hasAuthorship W2784286543A5045811414 @default.
• W2784286543 hasConcept C126322002 @default.
• W2784286543 hasConcept C185592680 @default.
• W2784286543 hasConcept C203014093 @default.
• W2784286543 hasConcept C2776155809 @default.
• W2784286543 hasConcept C2776530707 @default.
• W2784286543 hasConcept C2776715498 @default.
• W2784286543 hasConcept C55493867 @default.
• W2784286543 hasConcept C71924100 @default.
• W2784286543 hasConcept C8891405 @default.
• W2784286543 hasConcept C98274493 @default.
• W2784286543 hasConceptScore W2784286543C126322002 @default.
• W2784286543 hasConceptScore W2784286543C185592680 @default.
• W2784286543 hasConceptScore W2784286543C203014093 @default.
• W2784286543 hasConceptScore W2784286543C2776155809 @default.
• W2784286543 hasConceptScore W2784286543C2776530707 @default.
• W2784286543 hasConceptScore W2784286543C2776715498 @default.
• W2784286543 hasConceptScore W2784286543C55493867 @default.
• W2784286543 hasConceptScore W2784286543C71924100 @default.
• W2784286543 hasConceptScore W2784286543C8891405 @default.
• W2784286543 hasConceptScore W2784286543C98274493 @default.
• W2784286543 hasLocation W27842865431 @default.
• W2784286543 hasOpenAccess W2784286543 @default.
• W2784286543 hasPrimaryLocation W27842865431 @default.
• W2784286543 hasRelatedWork W1561633441 @default.
• W2784286543 hasRelatedWork W1964823747 @default.
• W2784286543 hasRelatedWork W2170658503 @default.
• W2784286543 hasRelatedWork W2183191043 @default.
• W2784286543 hasRelatedWork W2183366106 @default.
• W2784286543 hasRelatedWork W2184358025 @default.
• W2784286543 hasRelatedWork W2184726000 @default.
• W2784286543 hasRelatedWork W2545025364 @default.
• W2784286543 hasRelatedWork W2783237374 @default.
• W2784286543 hasRelatedWork W2783867083 @default.
• W2784286543 hasRelatedWork W2783982632 @default.
• W2784286543 hasRelatedWork W2957885507 @default.
• W2784286543 hasRelatedWork W2184183728 @default.
• W2784286543 hasRelatedWork W2184241267 @default.
• W2784286543 hasRelatedWork W2187168194 @default.
• W2784286543 hasRelatedWork W2187229876 @default.
• W2784286543 hasRelatedWork W2188107017 @default.
• W2784286543 hasRelatedWork W2572544717 @default.
• W2784286543 hasRelatedWork W2594391140 @default.
• W2784286543 hasRelatedWork W3149759352 @default.
• W2784286543 isParatext "false" @default.
• W2784286543 isRetracted "false" @default.
• W2784286543 magId "2784286543" @default.
• W2784286543 workType "dissertation" @default.